Randal J. Kirk

Randal J. Kirk (born March 1, 1954) is an American billionaire businessman and investor in pharmaceuticals and biotechnology. Kirk was the chairman and chief executive officer of Intrexon (NYSE: XON), a biotechnology company, until 2020. Kirk started as a lawyer, but is best known for his investments in pharmaceutical and biotech companies. In addition to high-profile sales of New River Pharmaceuticals, and Clinical Data, Kirk founded investment firm Third Security, and has held board seats with biotech companies, such as Scios. As of May 2024, Forbes estimated his net worth at US$1.4 billion.

Early life and education Randal J. Kirk was born in Pleasanton, California. The son of a U.S. Air Force master sergeant, Kirk and his family moved from California to Texas before settling in Virginia and Florida.

In 1996, Kirk founded New River Pharmaceuticals, where he served as chairman and CEO and took the company public in 2004. The developer of attention-deficit drug Vyvanse, New River would prove to be Kirk's single biggest payoff when he sold the company to Shire in 2007 for $2.6 billion, making over a $1 billion for Kirk himself.

In 1999, Kirk founded the life-sciences investment firm Third Security, LLC, where he is senior managing director, CEO and chairman. From 2000 to 2002, Kirk served as a member of the board of directors for Scios, Inc., a maker of heart disease medication that later sold to Johnson & Johnson for $2.4 billion. Kirk also became the majority stock holder and chairman of Newton, Massachusetts-based pharmaceutical company Clinical Data, Inc. In 2011, shortly after Clinical Data's drug Viibryd received regulatory approval, Forest Laboratories bought Clinical Data for $1.2 billion.

Kirk became involved with biotechnology company Intrexon in the 2000s. He was named chairman of its board in 2008 and became CEO in 2009. Kirk took Intrexon public in 2013, taking the company's market cap to $2.5 billion with the IPO. In early 2020, Intrexon adopted the name of its subsidiary, Precigen, and narrowed its focus to human gene editing. With the change in name the CEO of subsidiary Precigen, Helen Sabzevari, took over leadership of the company from Kirk.

Intrexon sold AquaBounty to TS Aquaculture, LLC, a privately held company managed by Third Security, LLC, a venture capital firm led by former Intrexon Chairman & CEO Randal Kirk. In addition to AquaBounty's development of genetically modified salmon, Kirk is involved in other companies advocating the approval of genetic engineering, including disease-resistant mosquitoes and an apple which resists browning. Other projects of Kirk's companies include creating cancer treatments, gasoline substitutes, crop protection, and improving bovine genetics.

Recognition Kirk has been profiled by SynBioBeta and Forbes. In 2008, Virginia Gov. Tim Kaine named Kirk Virginia's Outstanding Industrialist for the Year. He has spoken at the SynBioBeta Conference, Klick Ideas Exchange and was a Borlaug Dialogue Speaker at the World Food Prize.

Philanthropy and other roles Following the sale of General Injectables and Vaccines, Kirk donated $1 million to Radford University, creating the Zylphia Shu-En Kirk Endowment

Kirk has also donated substantially to political causes. He considers himself a political independent, and has supported both Republicans and Democrats. He has been especially involved in Virginia politics, donating $1.8 million to candidates for state office, including $200,000 to Terry McAuliffe's 2009 Virginia gubernatorial election.

Personal life Kirk lives in West Palm Beach, Florida and has four children.